Key Points
- Director Cyrus Harmon sold 12,500 Olema Pharmaceuticals shares at an average price of $11.58, generating $144,750. He retained 715,270 shares, reducing his position by 1.72%.
- OLMA shares were trading near $11.62, down 3.2%, with the stock well below its 200-day moving average of $16.79. The company remains unprofitable, reporting a quarterly loss of $0.52 per share.
- Analyst sentiment is mixed but leans positive, with an overall “Moderate Buy” rating and a $44.10 average price target, while institutional investors own 91.78% of the company.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 12,500 shares of the stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the transaction, the director owned 715,270 shares of the company's stock, valued at $8,282,826.60. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Olema Pharmaceuticals Trading Down 3.2%
Shares of OLMA opened at $11.62 on Wednesday. The business's 50-day moving average price is $11.56 and its 200 day moving average price is $16.79. The stock has a market capitalization of $1.02 billion, a P/E ratio of -5.75 and a beta of 2.00. Olema Pharmaceuticals, Inc. has a 1-year low of $4.47 and a 1-year high of $36.26. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). Analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.
Hedge Funds Weigh In On Olema Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the business. Siren L.L.C. purchased a new position in Olema Pharmaceuticals during the 4th quarter valued at about $82,518,000. Janus Henderson Group PLC lifted its position in shares of Olema Pharmaceuticals by 87.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company's stock worth $167,901,000 after purchasing an additional 3,124,345 shares in the last quarter. Cormorant Asset Management LP purchased a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth approximately $68,750,000. RA Capital Management L.P. acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth approximately $65,000,000. Finally, Bain Capital Life Sciences Investors LLC boosted its holdings in shares of Olema Pharmaceuticals by 24.3% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company's stock worth $212,716,000 after purchasing an additional 1,664,687 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.
Wall Street Analysts Forecast Growth
OLMA has been the topic of a number of recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Olema Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen cut shares of Olema Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday. HC Wainwright reiterated a "buy" rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Finally, Guggenheim cut their target price on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 13th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Olema Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $44.10.
View Our Latest Stock Report on Olema Pharmaceuticals
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
